What is the appropriate dosing regimen for Mimcipar (cinacalcet)?

Dosing Mimcipar (Cinacalcet)

For adults with secondary hyperparathyroidism on dialysis (CKD G5D), start cinacalcet at 30 mg once daily with food and titrate by 30 mg increments every 2-4 weeks up to a maximum of 180 mg/day, targeting PTH reduction while carefully monitoring for hypocalcemia—but reserve this therapy only for severe, progressive hyperparathyroidism refractory to standard treatment or when parathyroidectomy is contraindicated, as it does not improve mortality or cardiovascular outcomes. 1

Standard Adult Dosing Regimen

Initial Dosing

• Starting dose: 30 mg once daily with the main meal 2, 3
• Administer with food to optimize absorption 2

Dose Titration

• Increase by 30 mg increments every 2-4 weeks based on PTH response 2, 3
• Maximum dose: 180 mg/day (can be given as 90 mg twice daily at higher doses) 1, 3
• Target PTH levels of ≤250 pg/mL, though optimal PTH targets remain uncertain 1, 3

Alternative Dosing Schedule

• Twice-weekly dosing has been studied: 90 mg on day 1 and 120 mg mid-week, titrated monthly 2
• This regimen showed similar efficacy with potentially fewer side effects, though evidence is limited 2

Clinical Context and Indications

When to Use Cinacalcet

The 2017 KDIGO guidelines significantly restricted cinacalcet use based on lack of mortality benefit 1:

• Severe and progressive secondary hyperparathyroidism in dialysis patients (CKD G5D) that is refractory to standard therapy (phosphate binders and vitamin D analogs) 1
• When parathyroidectomy is contraindicated or patient refuses surgery 1
• Primary benefit: Prevention of parathyroidectomy (reduces risk by 51%, NNT = 3 per 1000 patient-years) 1

When NOT to Use Cinacalcet

• Do not use routinely for moderate PTH elevations in CKD G3a-G5 or dialysis patients 1
• No mortality benefit: High-quality evidence shows no effect on all-cause mortality (RR 0.97) 1
• Uncertain cardiovascular benefit: Effects on cardiovascular mortality remain unclear (RR 0.67) 1
• Consider parathyroidectomy first when feasible, as recent data suggest superior long-term survival and cardiovascular outcomes compared to cinacalcet 4

Monitoring Requirements

Before Initiation

• Baseline serum calcium, phosphate, and PTH levels 3, 5
• Assess for risk factors for hypocalcemia: catheter access, low albumin, high baseline PTH, diabetes, cardiovascular disease 5

During Treatment

• Monitor calcium levels closely, especially in first 12 months when 67% develop hypocalcemia 5
• Check calcium, phosphate, and PTH every 2-4 weeks during titration 3
• Once stable, monitor monthly 3

Adverse Effects and Management

Common Side Effects

• Hypocalcemia: Occurs in 67% of patients (9% severe), with 7.38-fold increased risk 1, 5
• Gastrointestinal effects: Nausea (2.05-fold increase, affects ~150 per 1000 treated), vomiting (1.95-fold), diarrhea (1.15-fold) 1
• Most hypocalcemia is asymptomatic and transient 5

Management of Hypocalcemia

• Reduce or hold cinacalcet dose 5
• Increase dialysate calcium concentration 1
• Add or increase calcium supplementation 5
• Most cases resolve without intervention 5

Pediatric Dosing

Children ≥2 Years on Dialysis

• Starting dose: 0.7 mg/kg/day (approximately 30 mg for average-sized child) 6, 7
• Titrate by 50% every 2-4 weeks to achieve PTH goal of 150-300 pg/mL 6
• Effective dose range: 2-3 mg/kg/day (median 2.8 mg/kg/day) 6
• Time to PTH goal: median 112 days 6
• Reserve for severe, refractory hyperparathyroidism after failure of standard therapy for >30 days 6, 7

Pediatric Monitoring

• More frequent calcium monitoring due to higher risk of hypocalcemia 6, 7
• Growth parameters should be tracked, as cinacalcet may support improved linear growth when PTH is controlled 6

Primary Hyperparathyroidism Dosing

For patients with primary hyperparathyroidism where surgery is contraindicated 8, 9:

• Starting dose: 30 mg twice daily 8
• Titrate up to 60 mg twice daily (maximum 90 mg four times daily in some studies) 9
• Target: Serum calcium ≤10 mg/dL 9
• 88% achieve ≥1 mg/dL reduction in calcium 9

Critical Caveats

Cost-Benefit Considerations

• High cost with limited benefit: Cinacalcet became the largest single drug cost for dialysis patients (>$260 million annually in US) without mortality benefit 1
• NNT vs NNH: Treating 1000 patients for 1 year prevents 3 parathyroidectomies but causes 60 cases of hypocalcemia and 150 cases of nausea 1

Guideline Controversy

• The 2017 KDIGO Update Work Group was divided on cinacalcet's role, with no consensus on first-line use 1
• The EVOLVE trial's primary endpoint was negative, though secondary analyses suggested possible benefits 1
• Current recommendation lists cinacalcet alphabetically with other options (calcitriol, vitamin D analogs), not as preferred therapy 1

Quality of Life Impact

• Gastrointestinal side effects may impair nutrition and quality of life 1
• No demonstrated improvement in patient-centered outcomes 1

Note: The FDA-labeled product "Mimcipar" in the evidence 10 appears to be a sodium fluoride toothpaste, not cinacalcet. The dosing recommendations above are for cinacalcet (the calcimimetic), which is the appropriate interpretation of the clinical question regarding hyperparathyroidism management.